Breast Cancer Coverage from Every Angle

George W. Sledge, MD, on HR+/HER2– Breast Cancer: Results From the MONARCH 2 Trial

Posted: Monday, June 5, 2017

George W. Sledge, MD, of Stanford University Medical Center, discussed study findings on abemaciclib in combination with fulvestrant in patients with HR-positive/HER2 negative advanced breast cancer who progressed on endocrine therapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.